- Pharmaceutical companies
- PharmaEngine
PharmaEngine
Phone: +886 2 2515–8228
Fax: +886 2 2515–7558
E-mail: info@pharmaengine.com
Web: https://www.pharmaengine.com/
PharmaEngine focuses on the development of new drugs for the treatment of cancer diseases. There are 2 projects in the pipeline. ONIVYDE® (PEP02, MM-398, nal-IRI), a new formulation of an anti-cancer drug (irinotecan) for the patients with gemcitabine-treated metastatic pancreatic cancer, so far, ONIVYDE® has received marketing approval in more than 40 countries, including Taiwan, US, EU, Australia, Canada, South Korea, and Japan. PEP07, a checkpoint kinase 1 (Chk1) inhibitor, which targets the DNA Damage Response (DDR) network, is currently in the pre-clinical stage.
For detailed contact information visit location pages below.
PharmaEngine's locations around the world
Asia
Clinical Trials sponsored by PharmaEngine
-
PharmaEngineConcluídoCâncer Colorretal MetastáticoTaiwan
-
PharmaEngineConcluído
-
PharmaEngineRecrutamentoLeucemia mielóide aguda | Linfoma de Células do MantoAustrália
-
PharmaEngineAinda não está recrutandoTumor Sólido Avançado | Tumor Sólido Metastático
-
PharmaEngineConcluídoTumores Sólidos RefratáriosTaiwan
-
PharmaEngineRescindido
-
PharmaEngineRescindidoCarcinoma Espinocelular de Cabeça e PescoçoTaiwan
-
PharmaEngineConcluídoNeoplasias PancreáticasTaiwan, Estados Unidos
-
PharmaEngineConcluídoNeoplasias do Estômago | Neoplasias EsofágicasRepublica da Coréia, Espanha, Taiwan, Bósnia e Herzegovina, Reino Unido, Croácia